Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bempegaldesleukin - Bristol Myers Squibb/Nektar Therapeutics

Drug Profile

Bempegaldesleukin - Bristol Myers Squibb/Nektar Therapeutics

Alternative Names: BEMPEG; Bempegaldesleukinum; BMS-986321; NKTR-214; ONO-7911

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics; University of Texas M. D. Anderson Cancer Center
  • Developer BioXcel Therapeutics; Bristol-Myers Squibb; Merck & Co; Nektar Therapeutics; Nykode Therapeutics; Ono Pharmaceutical; SFJ Pharmaceuticals; Takeda; Takeda Oncology; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antivirals; Immunotherapies; Interleukins; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Cancer; Colorectal cancer; COVID 2019 infections; Lymphoma; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 18 Jan 2024 Nektar Therapeutics and Bristol-Myers Squibb completes the phase I/II PIVOT IO 011 trial in Renal cell carcinoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic desease) in USA, Canada, Germany, Argentina, Brazil, France, Germany, Mexico and Russia (IV) (NCT04540705)
  • 31 Dec 2023 Discontinued - Phase-I for COVID-2019 infections (Combination therapy) in USA (IV)
  • 31 Dec 2023 Discontinued - Phase-I for Non-Hodgkin's lymphoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Canada (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top